Thyrocare

Analysts remain cautious on mid-and-smallcap segments and suggest earnings need to catch up before the stocks start to recover

Experts believe the current news cycle may keep the stock prices of related players volatile in the near term, but any fundamental or direct impact, in the long run, remains improbable.

A graduate of IIM-B, Guha has spent almost 17 years at Boston Consulting Group (BCG), where he has led the healthcare and life sciences practice

Realty firm Ashiana Housing on Saturday reported a consolidated net loss of Rs 5.2 crore for the quarter ending March. Its net loss stood at Rs 8.63 crore in the year-ago period

Of the three healthcare baskets that PharmEasy is targeting, it has already created a significant presence in consultation and treatment

I am an investor, and not insisting on any board seat. I am selling my entire stake of 66 per cent, says Velumani

Investors in Thyrocare should exit given the open offer discount to the current price

PharmEasy will retain the Thyrocare brand

The combined entity will have the ability to provide diagnostics and pharmacy services to 100 million-plus Indians within 24 hours, the company said in a statement

The second wave has been far more explosive than anticipated, affecting over 300,000 people a day. The sheer volume of the requirement hit the industry like a tonne of bricks

According to the Union Health Ministry data, India recorded 1,03,558 coronavirus infections on Sunday, pushing the nationwide Covid tally to 1.25 crore

Though details of Covid19-testing reimbursement are crucial to ascertain the earnings impact, other growth levers remain intact

They would start collecting samples for testing from today. For starters, this would happen in Mumbai

Velumani is inducting both his children into business with bigger share in the hands of daughter

The Rs 480-crore IPO is priced between Rs 420 and Rs 446 a share.

Its IPO price band is Rs 420-446 per share